ONCAlert | Upfront Therapy for mRCC

Liquid Biopsies VIEW MORE >>

Use of the liquid biopsy assay MSK-ACCESS has led to detection of actionable genetic variants in 40% of tumor samples, offering an attrac­tive alternative to invasive tumor biopsies in patients with no available tissue for testing. 

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.